Bidirectional interactions between astrocytes and neurons have physiological roles in the central nervous system and an altered state or dysfunction of such interactions may be associated with neurodegenerative diseases, such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Astrocytes exert structural, metabolic and functional effects on neurons, which can be either neurotoxic or neuroprotective. Their neurotoxic effect is mediated via the senescence-associated secretory phenotype (SASP) involving pro-inflammatory cytokines (e.g., IL-6), while their neuroprotective effect is attributed to neurotrophic growth factors (e.g., NGF). We here demonstrate that the p53 isoforms Δ133p53 and p53β are expressed in astrocytes and regulate their toxic and protective effects on neurons. Primary human astrocytes undergoing cellular senescence upon serial passaging in vitro showed diminished expression of Δ133p53 and increased p53β, which were attributed to the autophagic degradation and the SRSF3-mediated alternative RNA splicing, respectively. Early-passage astrocytes with Δ133p53 knockdown or p53β overexpression were induced to show SASP and to exert neurotoxicity in co-culture with neurons. Restored expression of Δ133p53 in near-senescent, otherwise neurotoxic astrocytes conferred them with neuroprotective activity through repression of SASP and induction of neurotrophic growth factors. Brain tissues from AD and ALS patients possessed increased numbers of senescent astrocytes and, like senescent astrocytes in vitro, showed decreased Δ133p53 and increased p53β expression, supporting that our in vitro findings recapitulate in vivo pathology of these neurodegenerative diseases. Our finding that Δ133p53 enhances the neuroprotective function of aged and senescent astrocytes suggests that the p53 isoforms and their regulatory mechanisms are potential targets for therapeutic intervention in neurodegenerative diseases.
Brain aging and neurodegenerative diseases remain major medical challenges of the twenty-first century. Alzheimer's disease (AD), the most common form of dementia, affects about 36 million people worldwide and is estimated to have cost $604 billion in 2010 alone. 1 Amyotrophic lateral sclerosis (ALS) is characterized by the loss of upper and lower motor neurons and life expectancy is 2-5 years following diagnosis. It is estimated to affect about 500 000 individuals in the USA alone and costs are $256-$433 million per year. 2 Despite continued scientific effort, few effective therapies exist for these neurodegenerative diseases.
Astrocytes are the most abundant cell type in the brain and have key roles in providing structural, functional, and metabolic support to neurons. 3 Although AD and ALS possess different etiologies, a commonality between these two diseases is the role of astrocytes in neurodegeneration. 4, 5 Dysfunctional neuron-astrocyte crosstalk is known to be a central feature of neurodegenerative diseases. 6, 7 Astrocytes exert both toxic and protective effects on neurons in a contextdependent manner. The neurotoxic effects of astrocytes are mediated in part through pro-inflammatory cytokines, such as interleukin-6 (IL-6). Overproduction of these factors is associated with human neurodegeneration 8 and murine models. 9 The neuroprotective effects of astrocytes are mediated through nerve growth factor (NGF) and insulin-like growth factor-1 (IGF-1), 10 which are deficient in neurodegenerative diseases 11, 12 and, to a lesser extent, during physiological brain aging. 13 Alexander disease, a rare astrocyte disease involving a mutation in the glial fibrillary acidic protein (GFAP), results in neurodegeneration. 14 Riluzole, a Food and Drug Administration-approved drug for ALS, targets a glutamate transporter, EAAT2, in astrocytes. 15 Thus, development of therapies targeting astrocytes is a subject of intense research. 4, 5 Cellular senescence is characterized by proliferation arrest after extensive cell divisions or upon cellular stresses. The characteristics of cellular senescence include enlarged cell morphology, upregulation of cell cycle inhibitors p16 INK4 (ref. 16 ) and p21 WAF1 , 17 senescence-associated β-galactosidase (SA-β-Gal) activity, 18 elevated nitric oxide synthase 2 (NOS2) associated with oxidative stress, 19, 20 and DNA double-strand breaks marked by phosphorylated H2AX (γH2AX). 21 Senescent cells secrete various cytokines, growth factors, and proteases that alter tissue microenvironment, which is collectively termed the senescence-associated secretory phenotype (SASP). 22 A major outcome of SASP is tissue inflammation and degeneration mainly through the activity of pro-inflammatory cytokines. In addition to these unfavorable effects, senescent cells and SASP can have beneficial roles in wound healing 23, 24 and embryonic development. [25] [26] [27] A main regulator of cellular stress responses and senescence is the TP53 gene. 28 The human TP53 encodes, in addition to full-length p53 protein, at least 12 natural protein isoforms through alternative mRNA splicing or alternative promoter usage. 29 Δ133p53, an N-terminal truncated isoform, functions as a negative regulator of cellular senescence by dominant-negatively inhibiting full-length p53. 30, 31 p53β, a C-terminal modified isoform, functions as a co-activator of full-length p53 to promote senescence. 30, 31 In this study, we report that Δ133p53 and p53β regulate the neuroprotective and neurotoxic functions of human astrocytes. Using a neuron-astrocyte co-culture system, we demonstrate that downregulation of Δ133p53 or upregulation of p53β in astrocytes promotes SASP and non-cell autonomous neurotoxicity. Furthermore, reconstituted expression of Δ133p53 in neurotoxic astrocytes prevents SASP and reverses them to neuroprotective astrocytes.
Results
Astrocytes express p53 isoforms, Δ133p53 and p53β, and their expression is regulated during cellular senescence. To examine whether p53 isoforms Δ133p53 and p53β are expressed in the human brain, immunofluorescence staining using Δ133p53-specific antibody MAP4 and p53β-specific antibody TLQ40 30, 31 was performed in non-disease human brain tissues (Supplementary Table S1 ). The specificity of the isoform-specific antibodies in immunofluorescence staining was confirmed using a p53-null cell line H358 with a Δ133p53, full-length p53, or p53β expression vector (Supplementary Figures S1A and B) . As astrocytes were reported to be a major cell type showing p53 immunoreactivity in non-neoplastic human brain tissues, 32, 33 we investigated whether the p53 isoforms would also be expressed in astrocytes and performed co-staining with astrocyte-specific marker glial fibrillary acidic protein (GFAP) (Figure 1a and Supplementary Figure S1C ). Both p53β and Δ133p53 signals were detected in GFAP-positive cells and localized within 4 0 ,6-diamidino-2-phenylindole (DAPI)-positive nuclei ( Figure 1a and Supplementary Figure S1C , arrows). Nuclei of GFAP-negative cells did not express the isoforms (Figure 1a , arrow heads). These findings indicate that astrocytes are the major cell type in the human brain that express Δ133p53 and p53β.
We examined whether in vitro cultured astrocytes also express the p53 isoforms. Primary human astrocytes 34 were serially passaged with monitoring by SA-β-gal staining and p16 INK4A (ref. 16 ) expression (Figures 1b and c ) and those at early passage (passage number 5) and approaching senescence (passage number 13) were examined in western blot analysis (Figure 1c ; Supplementary Figures S1D and E) . Fulllength p53 was upregulated during senescence. The Δ133p53-specific antibody detected a single band of 35 kDa corresponding to Δ133p53α 35 (simply called Δ133p53 in this manuscript) in early-passage astrocytes, which was diminished upon senescence. In contrast, p53β (47 kDa) was also upregulated upon senescence. These results indicate that human astrocytes express the p53 isoforms, Δ133p53 and p53β, whose expression profile at cellular senescence is conserved across different cell types. 30, 31 Autophagic degradation of Δ133p53 and SRSF3-mediated regulation of p53β in human astrocytes. To investigate whether increased p53β protein and decreased Δ133p53 protein in senescent astrocytes are due to regulation at the mRNA level, we performed qRT-PCR using RNA samples extracted from serially passaged astrocytes in vitro (passage numbers 5 and 13, as above). Similar levels of Δ133p53 mRNA were expressed at both passage numbers (Figure 2a) . p53β, by contrast, significantly increased at the mRNA level in astrocytes approaching senescence (Figure 2a ). These data indicate that Δ133p53 expression is mainly regulated at the protein level, whereas p53β is regulated at the mRNA level, as we previously reported in human fibroblasts and CD8 + T-lymphocytes. 30, 31 We tested whether Δ133p53 is degraded via selective autophagy in astrocytes, as we had previously reported in senescent fibroblasts and CD8 + T-lymphocytes. 31, 36 Senescent astrocytes (passage number 15) with low levels of Δ133p53 were treated with a pharmacological inhibitor of autophagy, bafilomycin A1, 37 whose action was confirmed by increased LC3-II 38 ( Figure 2b ). Treatment with bafilomycin A1 resulted in the upregulation of Δ133p53 in senescent astrocytes (Figure 2b ), suggesting that autophagic degradation of Δ133p53 contributes to its downregulation in these cells. The stabilization of Δ133p53 by bafilomycin A1 was also observed in an immortalized human astrocyte cell line 39, 40 (Supplementary Figure S2A) . Knockdown of p62/SQSTM1, which is a ubiquitin-binding adaptor specifically functioning in the selective autophagy pathway, 41 also stabilized Δ133p53 (Figure 2c) , further supporting the degradation of Δ133p53 via selective autophagy. In addition, whereas proteasome inhibitor MG132 stabilized full-length p53, Δ133p53 was not stabilized but rather decreased in astrocytes (Supplementary Figure S2B) , as previously observed in fibroblasts, 30 likely because of induction of autophagy by proteasome inhibition. 42, 43 As a splicing factor SRSF3 inhibits the p53 isoforms in neurodegeneration C Turnquist et al alternative mRNA splicing generating p53β in human fibroblasts and CD8 + T-lymphocytes, 31, 44 we examined whether SRSF3 regulates p53β in astrocytes as well. Knockdown of SRSF3 through small interfering RNA (siRNA) in immortalized astrocytes resulted in a significant increase in p53β mRNA (Figure 2d ), consistent with its negative regulation of p53β at the transcript level. These results indicate that the regulatory mechanisms for p53 isoform expression (autophagic degradation of Δ133p53 and SRSF3-mediated regulation of p53β splicing) are conserved in different cell types.
Δ133p53 knockdown or p53β overexpression induces cellular senescence and SASP in human astrocytes. We first recapitulated the senescence-associated expression signature (decreased Δ133p53 and increased p53β) in early-passage primary or immortalized human astrocytes to determine whether it induces these cells to senescence. Immortalized astrocytes were transfected with siRNA specifically targeting Δ133p53 45 or scramble siRNA control, followed by western blot analysis and immunofluorescence staining confirming Δ133p53 knockdown using Δ133p53-specific antibody MAP4 30, 31 (Figures 3a and b ; Supplementary Figure S3A ). Three days following Δ133p53 knockdown, cells became growth-arrested (Figure 3c , top panel) with vacuolization ( Figure 3c , bottom panel) and increased SA-β-gal staining (Figures 3d and e) , which are characteristics of cellular senescence. Increased mRNA expression of pro-inflammatory cytokines IL-6 and IL-1β, as well as p21 WAF1 , was also observed in these senescent cells (Figure 3f ), suggesting that loss of Δ133p53 induces SASP. Figure S3F) .
A lentiviral vector driving p53β expression or a vector control was transduced to immortalized astrocytes and its overexpression was confirmed by western blot analysis using a p53β-specific antibody 30, 31 ( Figure 4a ; Supplementary Figure S4A ). Similar to Δ133p53 knockdown, p53β overexpression inhibited cell proliferation (Figure 4b Figure S4B) were also growth-inhibited (Supplementary Figure S4C) , had increased SA-β-gal staining (Supplementary Figure S4D-E) , and induction of SASP (Supplementary Figure S4F) . As p53β has been shown to promote apoptosis and senescence by differentially regulating gene expression in different cell types, 29, 46, 47 cell viability as well as expression of Bax, p16 INK4 , and p21 was also assessed (Supplementary Figures S4G-I ). Percent cell viability was not significantly affected by overexpression of p53β (Supplementary Figure S4G) . Consistently, there was no difference in expression of the apoptosis regulator Bax (Supplementary Figure S4H) . In contrast, p21 and p16 expression were increased following p53β overexpression (Supplementary Figures S4H and I ). These results indicate that Δ133p53 downregulation and p53β upregulation have causative roles in inducing cellular senescence and SASP in astrocytes.
Increased neuronal death upon co-culture with Δ133p53-knocked-down or p53β-overexpressing astrocytes. To examine whether a phenotypic change in astrocytes (such as cellular senescence and SASP via Δ133p53 knockdown or p53β overexpression) alters astrocyte-to-neuron interaction, we utilized a co-culture system in which human primary astrocytes were co-plated with induced pluripotent stem cell (iPSC)-derived mature neurons, 48 followed by assays for neuronal survival and death (Supplementary Figures S5A  and B ). Mature neurons were derived from iPSC (Supplementary Figure S5C ) and confirmation of neuronal phenotypes was achieved through expression of sequential markers of differentiation: iPSCs expressed TRA-1-81 demonstrating pluripotency (Supplementary Figure S5D) ; neural stem cells (NSC) expressed Nestin and Sox1 (Supplementary Figure S5E ); and neurons expressed neuronal nuclei marker (NeuN) (Supplementary Figure S5F) . Motor neurons, a mature neuronal subtype that is primarily lost in ALS, were also derived from iPSC 49 and their differentiation was confirmed by expression of non-phosphorylated neurofilament marker, SMI-32 (Supplementary Figure S5G) .
When early-passage astrocytes with Δ133p53 siRNA or control siRNA (same cells as used in Supplementary Figure S3 ) were co-cultured with motor neurons for 48 h, Δ133p53-knocked-down, senescent astrocytes induced a higher number of neurons positive for cleaved caspase-3 To examine the effects of astrocytes on neurons in general and to obtain another quantitative measure, the co-culture experiment was performed using less specialized neurons (generated as in Supplementary Figure S5C ) and the number of surviving neurons (NeuNpositive) was counted after 48-h co-culture with astrocytes. A significant decrease in the number of surviving neurons was observed following co-culture with Δ133p53-knocked-down astrocytes (Figures 5e and f) or p53β-overexpressing astrocytes (Figures 5g and h ). An increase in neuronal apoptosis by p53β-overexpressing astrocytes was also confirmed in this experimental setting (Supplementary Figures S5H and I ). These findings indicate that the senescence-associated p53 isoform expression signature confers astrocytes with neurotoxic activity.
Δ133p53 protects astrocytes from senescence and enhances their neuroprotective function. The induction of astrocyte senescence and neurotoxicity by reproducing the senescence-associated p53 isoform expression signature ( Figures 3, 4 , and 5) prompted us to hypothesize that manipulated expression of the p53 isoforms (which in this case recapitulates the expression profile in early-passage astrocytes) may also lead to senescence inhibition and neuroprotective function in astrocytes. To test this hypothesis, Δ133p53 expression was reconstituted via lentiviral vector transduction in primary astrocytes approaching senescence (passage number 12) (Figure 6a ). Reconstituted expression of Δ133p53 restored cell proliferation (Figure 6b ), decreased SA-β-gal-positive cells (Figures 6b and c) , and reduced the levels of pro-inflammatory SASP cytokines IL-6 and IL-1β (Figure 6d ). Significantly, two neurotrophic growth factors, NGF and IGF-1, out of the three examined were two to WAF1 mRNA expression by Δ133p53 knockdown. qRT-PCR was performed in triplicate. Data are presented as mean ± S.E.M. *P ≤ 0.05, ***P ≤ 0.001 by unpaired two-tailed Student's t test p53 isoforms in neurodegeneration C Turnquist et al threefold upregulated by Δ133p53 reconstitution (Figure 6d ). Immunofluorescence staining of NGF confirmed its increased expression in Δ133p53-reconstituted astrocytes (Supplementary Figure S6A ), which was comparable with that in early-passage astrocytes (Supplementary Figure S6B) .
We then used these Δ133p53-reconstituted astrocytes in the co-culture experiment (as performed in Figure 5 ). Vector control-transduced astrocytes (derived from passage number 12) resulted in a much larger number of motor neurons positive for cleaved caspase-3 (35.0 ± 2.0%; Figures 6e and f) than those derived from passage number 5 (1.3 ± 0.3%; Figures 5a-d) , indicating a senescence-associated progression of neurotoxicity in astrocytes. The reconstitution of Δ133p53 in these near-senescent astrocytes significantly reduced the number of cleaved caspase-3-positive motor neurons (~12%; Figures 6e and f), suggesting that Δ133p53 in astrocytes functions to suppress neuronal apoptosis. Counting of NeuN-positive neurons following co-culture (Figures 6g  and h ) also showed that aged astrocytes were less neuroprotective than early-passage astrocytes (compare controls in Figure 6h versus Figures 5f and h), and that reconstituted expression of Δ133p53 restored the number of surviving neurons back to the level exerted by early-passage astrocytes (Δ133p53 in Figure 6h ; compare with controls in Figures 5f and h).
To confirm the roles of NGF and IL-6 in Δ133p53-mediated astrocyte neuroprotective and neurotoxic function, neutralizing antibodies were used in co-culture experiments. As a positive control for IL-6-neutralizing antibody, we first performed immunofluorescence staining of untreated neurons and neurons treated with IL-6 alone or both IL-6 and IL-6-neutralizing antibody (IL-6-NAb). Cleaved caspase-3 immunofluorescence staining was increased upon IL-6 treatment and reduced back to the control level upon co-incubation with IL-6-NAb (Supplementary Figure S6C) . Consistently, the number of NeuN-positive surviving neurons was significantly reduced upon IL-6 treatment and restored by IL-6-NAb ( Supplementary Figures S6C and D) . These results confirmed that IL-6 promotes neurotoxicity and that IL-6-NAb is effective at neutralizing its function. Next, we used IL-6-NAb in co-culture experiments with neurons and aged astrocytes (P12) (Figure 6i, Supplementary Figure S6E ). In these co-culture experiments, incubation with IL-6-NAb reduced neuronal apoptosis (indicated by cleaved caspase-3-positive neurons) to the level of Δ133p53-reconstituted astrocytes, but there was no combinatorial effect of Δ133p53 and IL-6-NAb over either alone (Figure 6i, Supplementary Figure S6E) . In co-culture experiments with NGF-neutralizing antibody (NGF-NAb), the reduction in neuronal apoptosis by Δ133p53 reconstitution was abolished by NGF-NAb, and thus the level of neuronal apoptosis in Δ133p53-reconstited astrocytes with NGF-NAb was similar to that in control astrocytes with or without NGF-NAb (Figure 6i, Supplementary Figure S6E) . These results indicate that Δ133p53 in astrocytes promotes Increased senescent astrocytes in brain tissues from neurodegenerative disease patients. To examine whether neurodegenerative disease tissues have increased features of cellular senescence, AD, ALS, age-matched non-disease, and non-disease pediatric tissues (Supplementary Table S1 ) were obtained. Immunohistochemical staining was performed using antibodies to proteins known to be associated with cellular senescence, such as p16 INK4A , 16 NOS2, 20 and γH2AX 21 ( Figure 7a ). An increase in the senescenceassociated biomarkers was prominent in all neurodegenerative samples examined compared with controls ( Figure 7a) . Quantification of the number of p16
INK4A -expressing cells revealed a significant increase in this senescence-associated gene in AD and ALS tissues (Figure 7b ). Although both AD and ALS are associated with increased cellular senescence, qRT-PCR using brain tissue RNA samples showed that SASP cytokine IL-6 and a p53-inducible senescence Figure 5 Increased neuronal death upon co-culture with Δ133p53-knocked-down or p53β-overexpressing astrocytes. Early-passage primary astrocytes (P5) with Δ133p53 siRNA and control siRNA (generated as in Supplementary Figure S3) (a, b, e, and f) and those with p53β -overexpression or control vector (generated as in Supplementary Figure S4 ) (c, d, g, and h) were used in co-culture for 48 h with motor neurons 49 or less specialized neurons (as generated as in Supplementary Figures S5C-F Data are presented as mean ± S.E.M. NS indicates P40.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 by unpaired two-tailed Student's t test p53 isoforms in neurodegeneration C Turnquist et al regulator p21 WAF1 were upregulated more remarkably in ALS, while NOS2 upregulation was more evident in AD (Figure 7c) , possibly reflecting the different disease pathologies. IL-6 and p21 WAF1 expression levels were much lower in pediatric brain tissues versus aged brain tissues (Supplementary Figure S7A) , indicating that these senescent changes not only are associated with neurodegenerative diseases, but also may occur during physiological brain aging. In agreement with astrocyte-like morphology of the senescent cells (Figure 7a ), immunofluorescence co-staining of p16 INK4A and GFAP as an astrocyte marker showed that the senescent cells were astrocytes (Figure 7d) . Furthermore, both immunohistochemical (Supplementary Figure S7B) and immunofluorescence staining (Supplementary Figure S7C) of GFAP showed the presence of astrocytes with enlarged and flattened cytoplasms, which is characteristic of senescent cells, 51 in AD and ALS brain tissues, but not in non-disease control tissues. . Scale bars = 10 μm. NS indicates P40.05, **P ≤ 0.01, ***P ≤ 0.001 by unpaired two-tailed Student's t test p53 isoforms in neurodegeneration C Turnquist et al p53β is upregulated and Δ133p53 is downregulated in neurodegenerative disease brains. To examine the expression of p53β and Δ133p53 in AD, ALS, and agematched non-disease brain tissues, western blot analysis was performed using the Δ133p53-specific antibody MAP4 and the p53β-specific antibody TLQ40, 30, 31 along with detection of fulllength p53. Only the 35 kDa Δ133p53 bands corresponding to Δ133p53α, but not smaller-size bands corresponding to Δ133p53β and Δ133p53γ, were detected by MAP4 in these brain tissues (Supplementary Figure S8A) . The major bands detected by TLQ40 were 47 kDa in size, which corresponds to p53β that starts at the same methionine as full-length p53, with smaller amounts of N-terminally truncated β isoforms (Supplementary Figure S8B) . These detection patterns are similar to those observed in primary human astrocytes (Figure 1c) . We found that full-length p53 (53 kDa) and p53β (47 kDa) were upregulated, whereas Δ133p53 (35 kDa) was downregulated, in AD and ALS tissues compared with nondisease tissues (Figure 8a ). Quantitative densitometric analysis determined that the upregulation of full-length p53 and p53β was two to threefold and the downregulation of Δ133p53 was 0.5-0.6-fold (Figure 8b ). The upregulation of p53β and the downregulation of Δ133p53 in neurodegenerative diseases are consistent with the expression profiles of these p53 isoforms observed in senescent astrocytes in vitro (Figure 1c) , as well as other in vivo conditions associated with increased senescence, such as pre-malignant colon adenomas 30 and CD8 + T-lymphocytes in the elderly. 31 The expression levels of Δ133p53 mRNA were not significantly changed between non-disease and AD or ALS tissues (Figure 8c ), while p53β mRNA was increased in AD and ALS compared with non-disease tissues (Figure 8d ), again in agreement with the observations in senescent astrocytes in vitro (Figure 2a ) and CD8 + T-lymphocytes in vivo. 31 A higher level of expression of Δ133p53 mRNA in non-disease pediatric tissues compared with non-disease aged brain tissues (Figure 8c ) may also suggest a transcriptional control of Δ133p53 during physiological brain development and aging. Thus, AD and ALS are associated with increased astrocyte senescence and the senescence-associated p53 isoform expression signature, validating that our in vitro experiments using serially passaged human astrocytes recapitulate part of in vivo pathology of these neurodegenerative diseases.
Discussion
Astrocytes exert both neuroprotective and neurodegenerative effects in a context-dependent manner, which are associated with either repression or induction of SASP, respectively. 52 The data are consistent with the notion that the astrocyte-mediated effects of the p53 isoforms on neurons are exerted through their regulatory roles for SASP (Figures 3f, 4e , and 6d and i, Supplementary Figure S6E) . One main feature of astrocyte SASP driving neuronal loss is the release of pro-inflammatory cytokines such as IL-6. 53 Consistent with the neurodegenerative role of these SASP cytokines, the induction of SASP in astrocytes either by Δ133p53 knockdown (Figure 3f ) or by p53β overexpression (Figure 4e ) leads to increased neuronal apoptosis (Figures 5a-d) , while the repression of astrocyte SASP by Δ133p53 restoration (Figure 6d ) leads to increased neuronal survival (Figures 6e and f) . Our data suggest that IL-6 is a therapeutic target in astrocytes to prevent neurotoxicity (Figure 9b ). The data also indicate that the upregulation of neurotrophic growth factors such as NGF and IGF-1 in astrocytes (Figure 6d, Supplementary Figure S6A ) mediates Δ133p53-induced neuroprotection (Figures 6g-i, Supplementary  Figure S6E ). NGF and IGF-1 are known to promote neuronal survival 54, 55 and are decreased in Alzheimer's and Parkinson's disease brain tissues. 11, 12 Furthermore, astrocytes utilize IGF-1 to protect neurons from oxidative stress. 56 Although this study focused on astrocyte-to-neuron signaling, possible roles of the p53 isoforms in neurons and neuron-toastrocyte signaling in neurodegenerative disease deserve further investigation.
Full-length p53 is known to transactivate pro-inflammatory cytokine genes such as IL-6 and IL-8. 57 It is thus likely that the effect of p53β or Δ133p53 on SASP and neurodegeneration is at least in part through cooperation with or dominant-negative inhibition of full-length p53. 30, 31 As full-length p53 functions to inhibit the IGF-1 signaling pathway, 58 the dominant-negative inhibition by Δ133p53 of full-length p53 activity 30 may increase IGF-1 signaling towards neuroprotection. Another possibility is that Δ133p53 may directly upregulate the neurotrophic factors NGF and IGF-1 through its gain-of-function activity, which was recently reported to activate a set of genes for DNA damage repair. 59 Although in silico analysis of the NGF and IGF-1 gene promoters did not identify a perfect match to the predicted Δ133p53-binding response element, 59 further studies will elucidate the regulation of these neurotrophic factors by Δ133p53 in dominant-negative and gain-of-function manners.
A phenotypic shift from neurotoxic SASP astrocytes to neuroprotective astrocytes may represent a promising therapeutic approach for inhibiting or delaying the progression of neurodegenerative diseases. In the proposed model (Figure 9 ), enhancement of Δ133p53 activity and/or inhibition of p53β activity could lead to such phenotypic shift of astrocytes. Because increased neurotoxicity, which was exerted by in vitro aged astrocytes and reverted by reconstituted expression of Δ133p53 in this study, is also characteristic of astrocytes derived from patients with neurodegenerative diseases, 60,61 our findings have implications in developing therapeutic interventions. This study provides a rationale for exploration of small molecules that can modulate the expression level or activity of the p53 isoforms to inhibit the progression of neurodegeneration. Finally, only humans and other primates have the equivalent of Δ133p53 (Supplementary Figure S9) . It is interesting whether this primate-specificity of Δ133p53 is related to primate-specific accumulation of β-amyloid 62 and other physiological or pathological processes specific or preferential to humans and other primates. Figure 9 Proposed models of the p53 isoform regulation of astrocyte-mediated neuroprotection and neurodegeneration. (a) The p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Δ133p53, which is regulated by selective autophagy-mediated degradation, 36 is abundant in early-passage astrocytes in vitro and astrocytes in non-disease brain tissues (here collectively termed 'young') and contributes to the neuroprotective function of these 'young' astrocytes. p53β, which is generated via alternative mRNA splicing, 44 is induced in senescent astrocytes in vitro and in neurodegenerative disease brain tissues and contributes to the neurotoxic effect of these senescent astrocytes. (b) IL-6 is a therapeutic target in astrocytes to prevent neurotoxicity. DNA damage and oxidative stress activate full-length p53 (FL-p53), which leads to transcriptional activation of IL-6 57 and neurotoxicity. The modulation of FL-p53 activity by the p53 isoforms, as well as IL-6-neutralizing antibody, prevents neurotoxicity p53 isoforms in neurodegeneration C Turnquist et al
Materials and Methods
Primary cells and cell lines. Primary human astrocytes were obtained from Sciencell (Carlsbad, CA, USA). 34 They were maintained in Astrocyte Medium supplemented with 2% fetal bovine serum, 1% astrocyte growth supplement from Sciencell, and 1% penicillin/streptomycin solution. When confluent, cells were split at a ratio of 1:4 (earlier passages) to 1:2 (later passages) until they reached replicative senescence. For immortalized human astrocytes, human fetal brain material was dissected from 8-to 12-week-old abortuses, aspirated through a 19-gauge needle, washed twice with Eagle's minimum essential medium and plated onto poly-D-lysine (0.1 mg/ml)-coated flasks. After 3 weeks, cells were transfected using calcium phosphate precipitation with a plasmid DNA containing the SV40 mutant with a deletion of its origin of replication (pMK16). 39, 40 H358 cells were purchased from American Type Culture Collection (Manassas, VA, USA).
Plasmid constructs. To generate retroviral expression vectors of human p53 isoforms, Flag-tagged p53β was PCR-amplified using pSVp53β and pSVDNp53, 29 respectively, as templates and then inserted into NotI and EcoRI sites of a pQCXIN vector (BD Biosciences, Franklin Lakes, NJ, USA). These constructs were verified by DNA sequencing. The Precision LentiORF RFP control vector (which drives RFP as an ORF insert, as well as IRES-translated GFP from the pLOC lentiviral vector backbone) was purchased from Open Biosystems/GE Dharmacon (Lafayette, CO, USA). For overexpression of p53β and Δ133p53, the RFP insert was replaced with cDNA inserts of p53β and Δ133p53, respectively.
Retroviral and lentiviral transduction. The retroviral constructs were transfected into Phoenix packaging cells (Orbigen, Inc., San Diego, CA, USA) using Lipofectamine 2000 (Invitrogen, Paisley, Renfrewshire, UK). Lentiviral supernatants were obtained using the Trans-lentiviral packaging system (Open Biosystems). Retro-and lentiviral vector supernatants were collected 48 h after transfection and used to infect cells in the presence of polybrene (8 μg/ml; Sigma-Aldrich, St. Louis, MO, USA). Two days after infection, the cells were selected with G418 (600 μg/ml; Sigma-Aldrich), puromycin (2 μg/ml; Sigma-Aldrich) or zeocin (1 mg/ ml; Invitrogen).
Transfection of siRNA oligonucleotides. siRNA oligonucleotides were transfected at a final concentration of 12 nM using Lipofectamine RNAiMAX (Invitrogen). The following oligonucleotides were from Invitrogen Stealth Select siRNA targeting Δ133p53: 5 0 -GGAGGUGCUUACACAUGUU-3 0 , 45 p62/SQSTM1: 5 0 -AGAAGUGGACCCGUCUACAGGUGAA-3 0 , 36 SRSF3: 5′-AGAGCUAGAUGGAA GAACATT-3′, 44 and Stealth non-specific RNAi negative control (no. 12,935-100).
SA-β-gal staining and cell treatments. SA-β-gal staining was performed with the Senescence-β-Galactosidase Staining Kit (Cell Signaling Technology, Danvers, MA, USA). Bafilomycin A1 was obtained from Sigma-Aldrich and incubated for 4 h at a concentration of 100 nM. MG132 was obtained from LC Laboratories (Woburn, MA, USA) and incubated for 8 h at a concentration of 15μM.
Cell viability assay. Cell pellets were resuspended in 20 ul of Trypan blue and cell viability was calculated using a TC20 Automated Cell Counter (Bio-Rad, Hercules, CA, USA).
Neuronal differentiation of iPSCs. The iPSC line, i20 (NIH stem cell bank), was differentiated to NSCs, and then to neurons using Gibco Pluripotent Stem Cell Neural Induction (Life Technologies, Frederick, MD, USA). For motor neuron differentiation, iPSCs were grown to 80% confluency, then digested with collagenase IV (Invitrogen) for 8 min. Cells were scraped off of the dish, and after settling, the supernatant was aspirated, and cells were re-plated into low adherence dishes (Corning, Corning, NY, USA) in KSR (Invitrogen)-based media with 20 ng/ml FGF (R&D Systems, Minneapolis, MN, USA), 20 μM ROCK-I (Tocris, Bristol, UK), 10 μM SB431542 (Tocris), and 0.2 μM LDN193189 (Stemgent). Embryoid bodies were transitioned to a KSR-free medium after 3 days. Retinoic acid was added to the media after 5 days to direct the cells towards a rostral spinal cord phenotype, with additional patterning using 1 μM smoothened agonist (Calbiochem, Billerica, MA, USA) and 0.5 μM purmorphamine (Stemgent, Cambridge, MA, USA) after 7 days to ventralize the differentiating population. After 14-16 days in suspension, the embryoid bodies were dissociated and plated on dishes coated with polyornithine or poly-D-lysine and laminin for an additional 7-14 days. Neuronal cultures were maintained in neurobasal media (Invitrogen) with 25 μM glutamate (Sigma, St. Louis, MO, USA), 0.4 μg/ml ascorbic acid (Sigma), 10 ng/ml GDNF (Sigma), 10 ng/ml CNTF (Sigma), 1 μg/ml laminin (BD Biosciences). B-27, N2, non-essential amino acids, and pen/strep/glutamine were all from Invitrogen. Two days after plating, 10 nM dihydrotestosterone was added, and the cultures were maintained for an additional 7-14 days.
Co-culture system. Following differentiation of iPSC to NSCs, NSCs were plated at a density of 3 × 10 4 cells/cm 2 in a four-well chamber slide coated with 20 μg/ml poly-L-ornithine and 10 μg/ml laminin. Media was changed to neural differentiation media (1 × Neurobasal Medium, 2% B-27 Serum-Free Supplement, 2 mM GlutaMAX-1 Supplement, Life Technologies) after 2 days. Media was changed every 3 days and NSCs were allowed to mature neurons for 1 month. Primary human astrocytes were plated on top of the mature neurons at a density of 3 × 10 4 cells/cm 2 . Media was changed to a 1:1 ratio of astrocyte (Sciencell) and neuron differentiation medium. 48, 63, 64 After 48 h, cells were fixed with 4% paraformaldehyde for immunocytochemistry staining. Percent apoptosis was calculated by counting number of cleaved caspase-3-, MAP2-, or NeuN-positive neurons in triplicate experiments in five microscopic fields (×40 magnification) for three biological replicates. In addition, the number of neurons remaining after the 48 h co-culture period was also quantified with five frames per condition for three biological replicates and counting the number of NeuN-positive neurons.
Recombinant IL-6 and neutralizing antibody treatments. Recombinant IL-6 (Invivogen, San Diego, CA, USA) was incubated for 24 h at a concentration of 5 ng/ml. In experiments with neutralizing antibodies, co-culture was performed as above with NGF neutralizing antibody (Alomone labs, Jerusalem, Israel) at a concentration of 500 ng/ml or IL-6 neutralizing antibody (Invivogen) at a concentration of 5 μg/ml. After 48 h, cells were fixed and stained as described above.
Immunohistochemistry and immunofluorescence. Frozen and formalin-fixed paraffin embedded human tissue sections were washed in PBS before blocking for 1 h in PBS containing 0.1% Triton-X and 10% donkey serum (Sigma-Aldrich). Donkey serum is used to block non-specific binding sites before incubation with primary antibody overnight at 4°C. Antigens were detected using the antibodies listed in Supplementary Table S2 . After overnight incubation, they were washed in PBS three times for 10 min, before incubation with the appropriate conjugated secondary antibodies for 1 h at room temperature. The secondary antibody was conjugated to fluorophores: Alexa-488, -568, and -647 (Invitrogen; 1:400). After washing in PBS three times for 10 min, sections were incubated for 10 min in 4',6-diamidino-2-phenylindole (10ug/ml, Sigma-Aldrich) to counterstain the cell nuclei, and rinsed three times for 10 min in 0.1 M phosphate buffer. Sections were mounted and slides coverslipped with FluorSave mounting medium (Millipore, Billerica, MA, USA). Omission of primary antibody was used as a negative control in all immunofluorescence experiments. For immunohistochemistry on paraffin sections, slides were heated to 65°C before immersion in histoclear and rehydration with graded alcohols. Sections were blocked in 1% H2O2 in PBS-Tween 20 (PBS-T) and then in 5% normal goat serum in PBS-T. Antigens were detected using the antibodies listed in Supplementary Table S2 . Binding of the primary antibody was detected using a biotinylated secondary antibody listed in Supplementary Table S3 with an ABC standard kit (Vector Laboratories, Burlingame, CA, USA). Visualization was enabled using a 0.05% diaminobenzene hydrochloride solution (Sigma-Aldrich). Omission of primary antibody was used as negative controls in all immunohistochemistry experiments.
Immunocytochemistry. Cells were washed with PBS and fixed for 10 min with 4% paraformaldehyde. Cells were permeabilized with 0.01% Triton-X for 4 min, washed with PBS and then blocked in 5% FBS for 1 h at room temperature. Primary antibodies listed in Supplementary Table S2 were applied overnight at 4°C. Cells were washed with PBS before incubation with a secondary antibody conjugated to fluorophores: Alexa-488, 568-and -647 at a dilution of 1:400 (Life Technologies) and 4',6-diamidino-2-phenylindole for 1 h. Coverslips were mounted on to slides with FluorSave mounting medium (Chemicon). Omission of primary antibody was used as a negative control in all immunocytochemistry experiments.
Immunoblotting. Cells and tissues were lysed in RIPA buffer. Lysates were kept on ice for 30 min prior to sonication. Protein concentration was measured using the Bradford assay method. NuPAGE 4 × loading buffer was added to all lysates and then boiled for 5 min. Then, 40 μg of protein was loaded onto a Tris-glycine gel Supplementary Table S2 overnight at 4°C, and washed three times in TBSTween-20. Membranes were then incubated in secondary antibody listed in Supplementary Table S3 for 1 h at room temperature and the signal visualized SuperSignal developing reagent and visualized using X-ray films (Fujifilm, Tokyo, Japan).
RNA extraction and cDNA preparation. mRNA was extracted using the RNeasy Mini Kit (Qiagen, Crawley, UK) according to the manufacturer's instructions. For mouse brain tissue, 10-20 mg of frozen cortical tissue was added to 300 μl lysis buffer containing 0.001% β-mercaptoethanol. Tissues or cells were homogenized and lysate mixed 1:1 with 70% ethanol and centrifuged through an RNeasy Mini Spin column. The column was washed and treated with DNAse 1 for 15 min, before washing again to remove contaminants. RNA was eluted with RNase-free water. The abundance and quality of the resulting RNA was assessed using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). RNA samples were diluted so that 200 ng total RNA could be used for a 25-μl reverse-transcription reaction. cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen). Statistical analysis. Data are presented as mean ± standard error of the mean (S.E.M.) of an n = 3 independent experiments unless otherwise stated. Statistical comparisons were made using unpaired two-tailed Student's t-test. Differences were considered significant at a value of *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. ImageJ software was used to quantify gel bands from immunoblots using densitometry.
